1、Basti S, Macsai MS. Ocular surface squamous neoplasia: a review[ J].
Cornea, 2003, 22(7): 687-704.Basti S, Macsai MS. Ocular surface squamous neoplasia: a review[ J].
Cornea, 2003, 22(7): 687-704.
2、Lee GA, Hirst LW. Ocular surface squamous neoplasia[ J]. Surv
Ophthalmol, 1995, 39(6): 429-450.Lee GA, Hirst LW. Ocular surface squamous neoplasia[ J]. Surv
Ophthalmol, 1995, 39(6): 429-450.
3、Margo CE, White AA. Ocular surface squamous neoplasia: terminology
that is conceptually friendly but clinically perilous[ J]. Eye (Lond),
2014, 28(5): 507-509.Margo CE, White AA. Ocular surface squamous neoplasia: terminology
that is conceptually friendly but clinically perilous[ J]. Eye (Lond),
2014, 28(5): 507-509.
4、Shields CL, Shields JA. Tumors of the conjunctiva and cornea[ J].
Indian J Ophthalmol, 2019, 67(12): 1930-1948.Shields CL, Shields JA. Tumors of the conjunctiva and cornea[ J].
Indian J Ophthalmol, 2019, 67(12): 1930-1948.
5、Theotoka D, Morkin MI, Galor A, et al. Update on diagnosis and
management of conjunctival papilloma[ J]. Eye Vis (Lond), 2019, 6: 18.Theotoka D, Morkin MI, Galor A, et al. Update on diagnosis and
management of conjunctival papilloma[ J]. Eye Vis (Lond), 2019, 6: 18.
6、Singh M, Gautam N, Gupta A , et al. Interferon alfa-2b in the
management of recurrent conjunctival papillomatosis[ J]. Indian J
Ophthalmol, 2016, 64(10): 778-780.Singh M, Gautam N, Gupta A , et al. Interferon alfa-2b in the
management of recurrent conjunctival papillomatosis[ J]. Indian J
Ophthalmol, 2016, 64(10): 778-780.
7、Rudkin AK, Dempster L, Muecke JS. Management of diffuse ocular
surface squamous neoplasia: efficacy and complications of topical
chemotherapy[ J]. Clin Exp Ophthalmol, 2015, 43(1): 20-25.Rudkin AK, Dempster L, Muecke JS. Management of diffuse ocular
surface squamous neoplasia: efficacy and complications of topical
chemotherapy[ J]. Clin Exp Ophthalmol, 2015, 43(1): 20-25.
8、王玉川, 陈陆霞, 李静, 等. 结膜日光性角化病的临床病理学特点
及其与HPV的关系[ J]. 中华眼科杂志, 2019, 55(7): 531-535.
WANG YC, CHEN LX, LI J, et al. The clinicopathological
features and HPV detection of conjunctival actinic keratosis[ J].
Chinese Journal of Ophthalmology, 2019, 55(7): 531-535.王玉川, 陈陆霞, 李静, 等. 结膜日光性角化病的临床病理学特点
及其与HPV的关系[ J]. 中华眼科杂志, 2019, 55(7): 531-535.
WANG YC, CHEN LX, LI J, et al. The clinicopathological
features and HPV detection of conjunctival actinic keratosis[ J].
Chinese Journal of Ophthalmology, 2019, 55(7): 531-535.
9、Shields JA, Shields CL. Eyelid, conjunctival, and orbital tumors:
an Atlas and textbook[M]. 2nd ed. St. Walnut: Philadelphia, 2008:
284-285.Shields JA, Shields CL. Eyelid, conjunctival, and orbital tumors:
an Atlas and textbook[M]. 2nd ed. St. Walnut: Philadelphia, 2008:
284-285.
10、Karp CL, Mercado C, Venkateswaran N, et al. Use of high-resolution
optical coherence tomography in the surgical management of ocular
surface squamous neoplasia: a pilot study[ J]. Am J Ophthalmol, 2019,
206: 17-31.Karp CL, Mercado C, Venkateswaran N, et al. Use of high-resolution
optical coherence tomography in the surgical management of ocular
surface squamous neoplasia: a pilot study[ J]. Am J Ophthalmol, 2019,
206: 17-31.
11、Shah SU, Kaliki S, Kim HJ, et al. Topical interferon alfa-2b for
management of ocular surface squamous neoplasia in 23 cases:
outcomes based on A mer ican Joint Committee on Cancer
classification[ J]. Arch Ophthalmol, 2012, 130(2): 159-164.Shah SU, Kaliki S, Kim HJ, et al. Topical interferon alfa-2b for
management of ocular surface squamous neoplasia in 23 cases:
outcomes based on A mer ican Joint Committee on Cancer
classification[ J]. Arch Ophthalmol, 2012, 130(2): 159-164.
12、Parrozzani R, Frizziero L, Trainiti S, et al. Topical 1% 5-fluoruracil as a
sole treatment of corneoconjunctival ocular surface squamous neoplasia:
long-term study[ J]. Br J Ophthalmol, 2017, 101(8): 1094-1099.Parrozzani R, Frizziero L, Trainiti S, et al. Topical 1% 5-fluoruracil as a
sole treatment of corneoconjunctival ocular surface squamous neoplasia:
long-term study[ J]. Br J Ophthalmol, 2017, 101(8): 1094-1099.
13、Galor A, Karp CL, Oellers P, et al. Predictors of ocular surface
squamous neoplasia recurrence after excisional surger y[ J].
Ophthalmology, 2012, 119(10): 1974-1981.Galor A, Karp CL, Oellers P, et al. Predictors of ocular surface
squamous neoplasia recurrence after excisional surger y[ J].
Ophthalmology, 2012, 119(10): 1974-1981.
14、Chalkia AK, Bontzos G, Spandidos DA, et al. Human papillomavirus
infection and ocular surface disease (Review)[ J]. Int J Oncol, 2019,
54(5): 1503-1510.Chalkia AK, Bontzos G, Spandidos DA, et al. Human papillomavirus
infection and ocular surface disease (Review)[ J]. Int J Oncol, 2019,
54(5): 1503-1510.
15、Santoni A, Thariat J, Maschi C, et al. Management of invasive
squamous cell carcinomas of the conjunctiva[ J]. Am J Ophthalmol,
2019, 200: 1-9.Santoni A, Thariat J, Maschi C, et al. Management of invasive
squamous cell carcinomas of the conjunctiva[ J]. Am J Ophthalmol,
2019, 200: 1-9.
16、Midena E, Angeli CD, Valenti M, et al. Treatment of conjunctival
squamous cell carcinoma with topical 5-fluorouracil[ J]. Br J Ophthalmol,
2000, 84(3): 268-272.Midena E, Angeli CD, Valenti M, et al. Treatment of conjunctival
squamous cell carcinoma with topical 5-fluorouracil[ J]. Br J Ophthalmol,
2000, 84(3): 268-272.
17、Venkateswaran N, Mercado C, Galor A, Karp CL. Comparison of
topical 5-fluorouracil and interferon alfa-2b as primary treatment
modalities for ocular surface squamous neoplasia[ J]. Am J Ophthalmol,
2019, 199: 216-222.Venkateswaran N, Mercado C, Galor A, Karp CL. Comparison of
topical 5-fluorouracil and interferon alfa-2b as primary treatment
modalities for ocular surface squamous neoplasia[ J]. Am J Ophthalmol,
2019, 199: 216-222.
18、Arepalli S, Kaliki S, Shields CL, et al. Plaque radiotherapy in the
management of scleral-invasive conjunctival squamous cell carcinoma:
an analysis of 15 eyes[ J]. JAMA Ophthalmol, 2014, 132(6): 691-696.Arepalli S, Kaliki S, Shields CL, et al. Plaque radiotherapy in the
management of scleral-invasive conjunctival squamous cell carcinoma:
an analysis of 15 eyes[ J]. JAMA Ophthalmol, 2014, 132(6): 691-696.